Ghrelin acts as an interface between physiological state and phasic dopamine signaling.
Brief, high-concentration (phasic) spikes in nucleus accumbens dopamine critically participate in aspects of food reward. Although physiological state (e.g., hunger, satiety) and associated hormones are known to affect dopamine tone in general, whether they modulate food-evoked, phasic dopamine specifically is unknown. Here, we used fast-scan cyclic voltammetry in awake, behaving rats to record dopamine spikes evoked by delivery of sugar pellets while pharmacologically manipulating central receptors for the gut "hunger" hormone ghrelin. Lateral ventricular (LV) ghrelin increased, while LV ghrelin receptor antagonism suppressed the magnitude of dopamine spikes evoked by food. Ghrelin was effective when infused directly into the lateral hypothalamus (LH), but not the ventral tegmental area (VTA). LH infusions were made in close proximity to orexin neurons, which are regulated by ghrelin and project to the VTA. Thus, we also investigated and found potentiation of food-evoked dopamine spikes by intra-VTA orexin-A. Importantly, intra-VTA blockade of orexin receptors attenuated food intake induced by LV ghrelin, thus establishing a behaviorally relevant connection between central ghrelin and VTA orexin. Further analysis revealed that food restriction increased the magnitude of dopamine spikes evoked by food independent of any pharmacological manipulations. The results support the regulation of food-evoked dopamine spikes by physiological state with endogenous fluctuations in ghrelin as a key contributor. Our data highlight a novel mechanism by which signals relating physiological state could influence food reinforcement and food-directed behavior.
Graduate Program in Neuroscience, University of Illinois at Chicago, Chicago, Illinois 60612 and Department of Psychology, University of Illinois at Chicago, Chicago, Illinois 60607.
Jackson J
JJ
Cone
James E
JE
McCutcheon
Mitchell F
MF
Roitman
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001583:Benzoxazoles / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005215:Fasting; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology; D054439:Ghrelin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007026:Hypothalamic Area, Lateral / Q000187:drug effects*; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D008297:Male; D009287:Naphthyridines; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D009842:Oligopeptides / Q000494:pharmacology; D000068797:Orexins; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology; D017557:Ventral Tegmental Area / Q000187:drug effects*; D014851:Wakefulness
C420062:1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea; D001583:Benzoxazoles; D054439:Ghrelin; D047908:Intracellular Signaling Peptides and Proteins; D009287:Naphthyridines; D009479:Neuropeptides; D009842:Oligopeptides; D000068797:Orexins; C048770:glycyl-histidyl-arginyl-proline; D014508:Urea; D004298:Dopamine
feeding; mesolimbic; nucleus accumbens; obesity; reward; voltammetry